Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108835 | 0.83 | NPC1 (0.54) | CDK5CDK5R1ALDH1A1NPC1RAB9A | |
| SCHEMBL1743706 | 0.81 | DYRK1A (0.54) | DYRK1APIK3CAPIK3CGALDH1A1NPC1 | |
| SCHEMBL22614984 | 0.76 | NPC1 (0.57) | CYP2C9ALDH1A1NPC1RAB9A | |
| SCHEMBL4024150 | 0.75 | F2RL3 (0.48) | FYNNPC1RAB9APDE10A | |
| Bromide SCHEMBL1691891 | 0.75 | NPC1 (0.56) | CYP2C9ALDH1A1NPC1RAB9A | |
| SCHEMBL23992875 | 0.75 | CYP2A6 (0.43) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL30224595 | 0.75 | CYP2A6 (0.43) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL31683146 | 0.75 | RAB9A (0.69) | DYRK1AALDH1A1AURKANPC1RAB9A | |
| SCHEMBL26603226 | 0.75 | RAB9A (0.69) | DYRK1AALDH1A1AURKANPC1RAB9A | |
| SCHEMBL2544254 | 0.74 | RAB9A (0.47) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202955-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2025-10-02 | — | — | WO | disclosed |
| US-20180368404-A1 | 3-PYRIDYL HETEROBICYCLIC COMPOUND FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2018-12-27 | — | — | US | disclosed |
| EP-3214936-A1 | 3-PYRIDYL HETEROBICYCLIC COMPOUND FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071499-A1 | 3-PYRIDYL HETEROBICYCLIC COMPOUND FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2016-05-12 | — | — | WO | disclosed |
| EP-2385946-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND TUERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-8040450-B2 | Liquid crystal electro-optic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010070238-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070238-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009027733-A1 | (2-PYRIDIN-3-YLIMIDAZO[1,2-B]PYRIDAZIN-6-YL) UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027733-A1 | (2-PYRIDIN-3-YLIMIDAZO[1,2-B]PYRIDAZIN-6-YL) UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180368404-A1 | 3-PYRIDYL HETEROBICYCLIC COMPOUND FOR CONTROLLING INVERTEBRATE PESTS | DDT, PIKFYVE, PIR | DYRK3 651/4885CCNA2 818/4885CDK2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.